| Price | 1,817.50p on 14-08-2026 at 18:35:07 |
|---|---|
| Change | -39.00p -2.1% |
| Buy | 1,813.50p |
| Sell | 1,812.50p |
| Last Trade: | Unknown 823,949.00 at 1,848.00p |
| Day's Volume: | 14,890,876 |
| Last Close: | 1,817.50p |
| Open: | 1,855.50p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,803.50p - 1,856.00p |
| 52wk Range: | 1,430.00p - 2,282.00p |
| Market Capitalisation: | £72.80b |
| VWAP: | 1,843.84357p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 823,949 | 1,848.00p | Negotiated Trade OTC Trade |
17:30:13 - 14-Aug-26 |
| Buy* | 100,000 | 1,813.685p | SI Trade |
17:05:09 - 14-Aug-26 |
| Buy* | 4,604 | 1,817.50p | Automatic Execution |
16:35:19 - 14-Aug-26 |
| Buy* | 100 | 1,817.50p | Automatic Execution |
16:35:19 - 14-Aug-26 |
| Buy* | 1,694 | 1,817.50p | SI Trade |
16:35:18 - 14-Aug-26 |
| Buy* | 7,099 | 1,817.50p | SI Trade |
16:35:18 - 14-Aug-26 |
| Buy* | 4,604 | 1,817.50p | Automatic Execution |
16:35:18 - 14-Aug-26 |
| Buy* | 700 | 1,817.50p | Automatic Execution |
16:35:18 - 14-Aug-26 |
| Buy* | 300 | 1,817.50p | Automatic Execution |
16:35:18 - 14-Aug-26 |
| Buy* | 4,604 | 1,817.50p | Automatic Execution |
16:35:18 - 14-Aug-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 13th Aug 2026 3:33 pm | RNS | Director/PDMR Shareholding |
| 11th Aug 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 3rd Aug 2026 3:00 pm | RNS | Total Voting Rights |
| 30th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 28th Jul 2026 12:05 pm | RNS | New GSK flagship R&D centre in Cambridge |
| 28th Jul 2026 12:00 pm | RNS | 2nd Quarter Results |
| 28th Jul 2026 11:06 am | RNS | Hansoh positive 2nd Phase III results for Riz-Rez |
| 24th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 24th Jul 2026 3:00 pm | RNS | Admission to Trading |
| 22nd Jul 2026 5:22 pm | RNS | Jideytro approved in US for certain lung cancers |
